Real‑world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia
Real-world evidence suggests that monotherapy and combination therapy tofacitinib is an effective intervention in RA with persistence and effectiveness comparable to bDMARDs.
Despite recommendations from EULAR that bDMARDs and tsDMARDs be used in combination with csDMARDs for the treatment of RA, it is estimated that up to a third of patients take their medication as monotherapy.
This post hoc analysis of data from the Australian OPAL study by Bird, et al. aimed to describe the real-world effectiveness and treatment persistence among patients with RA treated with monotherapy and combination therapy tofacitinib and bDMARDs.